Updates matching "Health Insurance Affordability"

MONTGOMERY, Ala. – April 22, 2025 – “We continue to have grave concerns about the harmful effects SB84 and HB477 would have on Alabamians, especially after the failure of amendments that would have added oversight and patient protections. There’s a reason why these plans are currently illegal. If state lawmakers

BISMARCK, ND -– North Dakota legislators made strong moves against cancer this session, passing bills on prior authorization reform and co-pay accumulator adjustments. The last of those bills – House Bill 1216 – passed the ND Senate on Monday and awaits Gov. Kelly Armstrong’s signature. Advocates of the American Cancer

Today, the American Cancer Society Cancer Action Network (ACS CAN) submitted comments in a letter to the Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) opposing the 2025 Marketplace Integrity Proposed Rule.

This week, the U.S. House of Representatives is expected to vote on a budget resolution that could lead to devastating cuts to Medicaid.

BISMARCK, N.D. –– A week after receiving a “do not pass” in committee, House Bill 1283 passed the full Senate on Monday behind strong Senate voices who took a stand on behalf of North Dakotans who might need additional breast cancer screenings beyond mammograms. HB 1283, sponsored by Rep. Karen

BISMARCK, N.D. – The North Dakota Senate on Monday passed House Bill 1216 on a 30-14 vote, setting aside a “Do Not Pass” by the Senate Human Services Committee and sending the bill back to Senate Appropriations for review and approval of amendments. The original bill passed the house on

This week, the U.S. House of Representatives is expected to consider a budget resolution that could lead to devastating cuts to Medicaid. Ahead of the vote, the American Cancer Society Cancer Action Network (ACS CAN) is urging House members to oppose cuts to Medicaid.

Eighty-six percent of cancer patients and survivors who receive tax credits to afford Marketplace plans say they would have difficulty getting the care they need without the enhanced premium tax credits, according to the latest Survivor Views survey from ACS CAN.

Washington, D.C. - Today, the Biden Administration released the list of 15 drugs for the next round of Medicare price negotiation, including four drugs to treat cancer: Xtandi to treat prostate cancer, Pomalyst to treat multiple myeloma, Ibrance to treat breast cancer, and Calquence to treat blood cancers including Chronic